Browning is conversion of white to brown-like adipocyte which is considered an attractive therapeutic strategy for the treatment of human obesity. Brown-like (Beige) adipocyte can be induced under different conditions, and this conversion is associated with decreased body weights and improving NAFLD via non-shivering thermo-genesis (NST). Accordingly, the pharmacological manipulation of browning may provide a means of influencing overall energy metabolism. There are multiple fat browning-related genes which are inducible, and their expression can be stimulated.Browning involves the expression of many transcription factors, such as PR domain containing 16 (PRDM16) and peroxisome proliferator-activated receptor (PPAR)-γ, and of uncoupling protein (UCP)-1, which is the hallmark of thermogenesis. Recent papers pointed that browning can occur in the WAT of humans, with beneficial metabolic effects. This fact indicates that these cells can be targeted to treat a range of diseases, with both pharmacological and nutritional activators. Pharmacological approaches to induce browning include the use of peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, adrenergic receptor stimulation, thyroid hormone administration, irisin and FGF21 induction. Most of them act through the induction of peroxisome proliferator-activated receptor-gamma coactivator (PGC) 1-α and the consequent mitochondrial biogenesis and UCP1 induction. About the nutritional inducers, several compounds have been described with multiple mechanisms of action. Some of these activators include specific amino acids restriction, capsaicin, bile acids, Resveratrol, and retinoic acid. Besides that, some classes of lipids, as well as many plant extracts, have also been implicated in the browning of WAT. In conclusion, the discovery of browning in human WAT opens the possibility to target the adipose tissue to fight a range of diseases. Studies have arisen showing promising results and bringing new opportunities in thermogenesis and obesity control